Expressions of survivin, P16INK4a, COX-2, and Ki-67 in cervical cancer progression reveal the potential clinical application

Purpose of investigation: To explore the significance of survivin, P16INK4a, COX-2, and Ki-67 expressions for prediction of cervical cancer progression. Materials and Methods: A retrospective study was performed in 129 cases including 24 squamous carcinoma of the cervix (SCC), 70 cervical intraepithelial neoplasias (CIN), 15 cervical condyloma acuminatum (CCA), ten chronic cervicitis (CC), and ten normal cervix (NC). Protein expressions were evaluated using immunohistochemistry. Results: Survivin, P16INK4a; COX-2, and Ki- 67 were highly expressed in SCC and CIN compared with others. Their expression rates were gradually increased in CIN I, CIN II, CIN III, and SCC groups, showing 72.00%, 88.00%, 90.00%, and 95.83% for P16INK4a, 68.00%, 84.00%, 95.00% and 100.00% for COX-2, 76.00%, 96.00%, 100.00%, and 100.00 for Ki-67, respectively. There were significant correlations between survivin and P16INK4a, COX-2, Ki-67, as well as P16INK4a and Ki-67. Conclusion: Survivin, P16INK4a, COX-2 and Ki-67 play critical roles for development and progression of cervical cancer.

Cervical cancer; Survivin; P16INK4a; Cyclooxygenase-2; Ki-67; Immunohistochemistry.

[1] Koh W.J., Greer B.E., Abu-Rustum N.R., Apte S.M., Campos S.M., Chan J., et al.: “Cervical cancer”. J. Natl. Compr. Canc. Ne., 2013, 11, 320.

[2] Ferlay J., Shin H., Bray F., Forman D., Mathers C., Parkin D.: “GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC Cancer Base No. 10”. Lyon, France: International Agency for Research on Cancer, 2010, Available at: http://www.iarc.fr/en/mediacentre/ iarcnews/2010/globocan2008.php

[3] Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D.: "Global cancer statistics". CA Cancer J. Clin., 2011, 61, 69. doi: 10.3322/caac.20107. Epub 2011 Feb 4.

[4] Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al.: “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide”. J. Pathol., 1999, 189, 12.

[5] Kuo J.H.S., Lin C.W.: “Cellular uptake on N-and C-termini conjugated FITC of Rath cell penetrating peptides and its consequences for gene-expression profiling in U-937 human macrophages and HeLa cervical cancer cells”. J. Drug Targ., 2013, 21, 801. doi: 10.3109/1061186X.2013.824456. Epub 2013 Aug 13.

[6] Tsakogiannis D., Papadopoulou A., Kontostathi G., Ruether I. G.A., Kyriakopoulou Z., Dimitriou T. G., et al.: “Molecular and evolutionary analysis of HPV16 E6 and E7 genes in Greek women”. J. Med. Microbiol., 2013, 62, 1688.

[7] Lee J.P., Chang K.H., Han J.H., Ryu H.S.: “Survivin, a novel anti‐apoptosis inhibitor, expression in uterine cervical cancer and relationship with prognostic factors”. Int. J. Gynecolog. Cancer, 2005, 15, 113.

[8] Agoff S.N., Lin P., Morihara J., Mao C., Kiviat N.B., Koutsky L.A.: “p16INK4a expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types”. Modern Pathol., 2003, 16, 665.

[9] Kulkarni S., Rader J. S., Zhang F., Liapis H., Koki A.T., Masferrer J.L., et al.: “Cyclooxygenase-2 is overexpressed in human cervical cancer”. Clin. Cancer Res., 2001, 7, 429.

[10] Zhang H.Y., Yang G.H., Chen H.J., Wei B., Ke Q., Guo H., et al.: “Clinicopathological, immunohistochemical, and ultrastructural study of 13 cases of melanotic schwannoma”. Chin. Med. J. (Engl), 2005, 118, 1451.

[11] Kawasaki H., Altieri D.C., Lu C.D., Toyoda M., Tenjo T., Tanigawa N.: “Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer”. Cancer Res., 1998, 58, 5071.

[12] Bowen A.R., Hanks A.N., Murphy K.J., Florell S.R., Grossman D.: “Proliferation, apoptosis, and survivin expression in keratinocytic neoplasmsand hyperplasias”. Am. J. Dermatopathol., 200 4, 26, 177.

[13] Shin S., Sung B.J., Cho Y.S., Kim H.J., Ha N.C., Hwang J.I., et al.: “An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and-7”. Biochemistry, 2001, 40, 1117.

[14] Li F.: “Role of survivin and its splice variants in tumorigenesis”. British J. Cancer, 2004, 92, 212.

[15] Kim H.S., Shiraki K., Park S.H.: “Expression of survivin in CIN and invasive squamous cell carcinoma of uterine cervix”. Anticancer Res., 2001, 22, 805.

[16]Branca M., Giorgi C., Santini D., Di Bonito L., Ciotti M., Costa S., : “Survivin as a marker of cervical intraepithelial neoplasia and highrisk human papillomavirus and a predictor of virus clearance and prognosis in cervical cancer”. Am. J. Clin. Pathol., 2005, 124, 113.

[17]Zindy F., Quelle D.E., Roussel M.F., Sherr C.J.: “Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging”. Oncogene, 1997, 15, 203.

[18]Klaes R., Friedrich T., Spitkovsky D., Ridder R., Rudy W., Petry U., et al.: “Overexpression of p16INK4a as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri”. Int. J. Cancer, 2001, 92, 276.

[19] Negri G., Egarter-Vigl E., Kasal A., Romano F., Haitel A., Mian C.: “p16INK4a is a useful marker for the diagnosis of adenocarcinoma of the cervix uteri and its precursors: an immunohistochemical study with immunocytochemical correlations”. Am. J. Surg. Pathol., 2003, 27, 187.

[20] Murphy N., Ring M., Heffron C., King B., Killalea A., Hughes C., et al.: “p16INK4A, CDC6, and MCM5: predictive biomarkers in cervicalpreinvasive neoplasia and cervical cancer”. J. Clin Patho l., 2005, 58, 525.

[21] Kargman S.L., O'Neill G.P., Vickers P.J., Evans J.F., Mancini J.A., Jothy S.: “Expression of prostaglandin G/H synthase-1 and-2 protein in human colon cancer”. Cancer Res., 1995, 55, 2556.

[22] Plescia O.J., Smith A.H., Grinwich K.: “Subversion of immune system by tumor cells and role of prostaglandins”. Pro. Natl. Acad. Sci., 1975, 72, 1848.

[23] Sheng H., Shao J., Morrow J.D., Beauchamp R.D., DuBois R.N.: “Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells”. Cancer Res., 1998, 58, 362.

[24] Ryu H.S., Chang K.H., Yang H.W., Kim M.S., Kwon H.C., Oh K.S.: “High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion”. Gynecol. Oncol., 2000, 76, 320.

[25] Portari E.A., Russomano F.B., de Camargo M.J., Gayer C.R.M., da Rocha Guillobel H.C., Santos-Rebouças C.B., et al.: "Immunohistochemical Expression of Cyclin D1, p16Ink4a, p21WAF1, and Ki-67 correlates with the severity of cervical neoplasia". Int. J. Gynecol., Pathol., 2013, 32, 501.

[26] Scholzen T., Gerdes J.: “The Ki‐67 protein: from the known and the unknown”. J. Cell. Physiol., 2000, 182, 311.

[27] Sahebali S., Depuydt C., Segers K., Vereecken A., Van Marck E., Bogers J.: “Ki-67 immunocytochemistry in liquid based cervical cytology: useful as an adjunctive tool?”. J. Clin. Pathol., 2003, 56, 681.

[28] Van Niekerk D., Guillaud M., Matisic J., Benedet J.L., Freeberg J.A., Follen M., et al.: “p16 and MIB1 improve the sensitivity and specificity of the diagnosis of high grade squamous intraepithelial lesions: methodological issues in a report of 447 biopsies with consensus diagnosis and HPV HCII testing”. Gynecol. Oncol., 2007, 107, S233.

[29] Glenn McCluggage W.: “Immunohistochemistry as a diagnostic aid in cervical pathology”. Pathology, 2007, 39, 97.

[30] Rokita W., Skawiński D., Zmelonek-Znamirowska A., Kedzia W., Karowicz-Bilińska A., Spaczyński R., et al.: “Results of pap smears and immunocytochemical detection of the p16 and Ki67 proteins in women with cervical intraepithelial neoplasia and cervical cancer”.Ginekol. Pol., 2012, 83, 822. [31] Kruse A.J., Gudlaugsson E., Helliesen T., Janssen E. A., van Diermen B., Sandvik S., Baak J.P.: “Evaluation of prospective, routine application of Ki-67 immunoquantitation in early CIN for assessment of short-term progression risk”. Anal. Quant. Cytol. Histol., 2004, 26, 134.

[32] Carreras R., Alameda F., Mancebo G., García Moreno P., Mariñoso M., Costa C., et al.: “A study of Ki-67, c-erbB2 and cyclin D-1 expression in CIN-I, CIN-III and squamous cell carcinoma of the cervix”. Histol. Histopathol., 2007, 22, 587.

[33] Pyeon D., Newton M. A., Lambert P. F., Den Boon J. A., Sengupta S., Marsit C. J., et al.: “Fundamental Differences in Cell Cycle Deregulation in Human Papillomavirus–Positive and Human Papillomavirus– Negative Head/Neck and Cervical Cancers”. Cancer Res., 2007, 67, 4605.

[34] Nakayama K.I., Nakayama K.: “Ubiquitin ligases: cell-cycle control and cancer”. Nat. Rev. Cancer, 2006, 6, 369.

[35] Indarti J., Aziz M.F., Sutrisna B., Siregar N.C., Suryawati B., Harahap A.: “Demographic characteristics, risk factors and immunocytochemistry of p16INK4a, Ki-67, MCM5, and survivin as predictors for the progress of cervical precancer lesion”. Med. J. Indones., 2010, 19, 147

[36] Ambrosini G., Adida C., Altieri D. C.: “A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma”. Nature Med., 1997, 3, 917.

[37] Suzuki A., Hayashida M., Ito T., Kawano H., Nakano T., Miura M., et al.: “Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16 (INK4a) and Cdk2/cyclin E complex activation”. Oncogene, 2000, 19, 3225.

[38] Ito T., Shiraki K., Sugimoto K., Yamanaka T., Fujikawa K., Ito M., et al.: “Survivin promotes cell proliferation in human hepatocellular carcinoma”. Hepatology, 2000, 31, 1080.

[39] Grösch S., Tegeder I., Niederberger E., Bräutigam L., Geisslinger G.: “COX-2 independent induction of cell cycle arrest and apoptosis incolon cancer cells by the selective COX- 2 inhibitor celecoxib”. FASEB J., 2001, 15, 2742.

[40] Quelle D.E., Cheng M., Ashmun R. A., Sherr C.J.: “Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF”. Pro. Natl. Acad. Sci., 1997, 94, 669.

[41] Gerdes J., Lemke H., Baisch H., Wacker H.H., Schwab U., Stein H.: “Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67”. J. Immunol., 1984, 133, 1710.

[42] Erkanli S., Bolat F., Kayaselcuk F., Demirhan B., Kuscu E.: “COX-2 and survivin are overexpressed and positively correlated in endometrial carcinoma”. Gynecol. Oncol., 2007, 104, 320.

[43] Nasr M.R., El-Zammar O.: “Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions”. Am. J. Dermatopathol., 2008, 30, 117.

[44] Yu L., Wang L., Zhong J., Chen S.: “Diagnostic value of p16INK4A, Ki‐67, and human papillomavirus L1 capsid protein immunochemical staining on cell blocks from residual liquid‐based gynecologic cytologyspecimens”. Cancer Cytopathol., 2010, 118, 47.

[45] Reuschenbach M., Seiz M., Doeberitz C., Vinokurova S., Duwe A., Ridder R., et al.: “Evaluation of cervical cone biopsies for coexpression of p16INK4a and Ki‐67 in epithelial cells”. Int. J. Cancer, 2012, 130, 388.